Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

NCT02559791 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Severe Persistent Asthma
Eosinophilic Bronchitis

Interventions

BIOLOGICAL: Reslizumab
DRUG: Placebo

Sponsor

McMaster University

Collaborators

[object Object]
[object Object]